EMPOWER-Lung3: Cemiplimab Plus Chemotherapy in Advanced NSCLC

Opinion
Video

Edgardo Santos, MD, FACP, FCCP, analyzes the influence on clinical practice arising from the application of cemiplimab with chemotherapy in advanced non-small cell lung cancer (NSCLC) observed in the EMPOWER-Lung3 trial.

Related Videos
Stephen V. Liu, MD
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Millie Das, MD
Video 10 -"Real-World Evidence on Second-Line Therapy Selection and Outcomes"
Video 9 - "Additional Second-Line Treatments for HCC"
A panel of 4 experts on colorectal cancer
A panel of 5 experts on lung cancer
A panel of 5 experts on lung cancer
Video 8 - "The Evolving Landscape of Second-Line Therapies in HCC Management"
Related Content
FDA

FDA Grants Breakthrough Therapy Designation to NVL-655 for Pretreated ALK+ NSCLC

May 17th 2024
Article
Hari B. Keshava, MD

Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection

October 23rd 2023
Podcast
FDA Grants Accelerated Approval to Tarlatamab for ES-SCLC

FDA Grants Accelerated Approval to Tarlatamab for ES-SCLC

May 16th 2024
Article
Adnan F. Danish, MD

Danish Discusses the Benefits of SCINTIX Biology-Guided Radiotherapy in Metastatic Lung and Bone Cancers

August 7th 2023
Podcast
FDA

OncLive’s April Roundup of Key FDA Decisions in Oncology

May 14th 2024
Article
Anne Chiang, MD, PhD, of Yale School of Medicine

Applying the Heterogeneous Approach From NSCLC to SCLC

May 14th 2024
Article